Drug Trial Radar · NCT04631016
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
Last checked: Nov 20, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
137
Actual
Start
Dec 14, 2020
Primary completion
May 30, 2023
Study completion Nov 13, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Bronchitis
Interventions
TozorakimabDrug
Participants will receive SC injection of tozorakimab as stated in arm description.
PlaceboOther
Participants will receive SC injection of placebo as stated in arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in ClinicTime frame: Baseline (Day -35 to Day -28) through Week 12
Locations
90 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Sheffield, Alabama
Research Site
Newport Beach, California
Research Site
Newark, Delaware
Research Site
Kissimmee, Florida
Research Site
Ormond Beach, Florida
Research Site
Winter Park, Florida
Research Site
Lakeside Park, Kentucky
Research Site
White Marsh, Maryland
Research Site
Ann Arbor, Michigan
Research Site
New Bern, North Carolina
Research Site
Columbus, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Pittsburgh, Pennsylvania
Research Site
North Charleston, South Carolina
Research Site
Spartanburg, South Carolina
Research Site
Boerne, Texas
Research Site
Nedlands, Australia
Research Site
South Brisbane, Australia
Research Site
Spearwood, Australia
Research Site
Tarragindi, Australia
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
Ajax, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Trois-Rivières, Quebec, Canada
Research Site
Brno, Czechia
Research Site
Olomouc, Czechia
Research Site
Písek, Czechia
Research Site
Prague, Czechia
Research Site
Rokycany, Czechia
Research Site
Aalborg, Denmark
Research Site
Hvidovre, Denmark
Research Site
København NV, Denmark
Research Site
Næstved, Denmark
Research Site
Odense C, Denmark
Research Site
Bamberg, Germany
Research Site
Berlin, Germany
Research Site
Berlin, Germany
Research Site
Darmstadt, Germany
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.